Thorough QT study to evaluate the effect of amifampridine on cardiac repolarisation in healthy volunteers
Phase of Trial: Phase I
Latest Information Update: 31 May 2016
Price : $35 *
At a glance
- Drugs Amifampridine (Primary)
- Indications Lambert-Eaton myasthenic syndrome
- Focus Adverse reactions
- 07 Apr 2014 New trial record
- 08 Jan 2014 Primary endpoint 'QT-interval' has been met, according to Catalyst Pharmaceutical Partners media release.
- 08 Jan 2014 Positive safety results reported in Catalyst Pharmaceutical Partners media release.